BioSpace News Archive

CoapTech, Inc, a medical device company focused on delivering transformative solutions for minimally-invasive surgery, announced today publication of study results conducted at the University of Maryland Baltimore Washington Medical Center (UM BWMC) comparing percutaneous gastrostomies placed with the PUMA-G System™ to those placed with usual care methods.

Vital Heart & Vein, a leading provider of cardiovascular and vein health, has named Gay Nord as its new chief executive officer.

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company’s telehealth program went live on May 6, 2022 for Mytesi (crofelemer), Jaguar’s FDA-approved antidiarrheal prescription drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

ReGrasp Bionic Glove, a medical device designed to help patients speed hand rehabilitation following a stroke or injury, is now available in the United States for patients to use at home or in a clinical setting.

AbbVie today announced positive topline results from U-ENDURE, its Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn’s disease who had an inadequate response or were intolerant to a conventional or biologic therapy.

Evolus, Inc. announced that members of its management team will be participating in the H.C. Wainwright Global Investment Conference.

Rakovina Therapeutics Inc., a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the presentation of new data during the 2022 AACR Special Conference on Sarcomas in Montreal, Canada.

Scilex Holding Company (“Scilex”), and a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today that safety data from Scilex’s Phase 1 clinical trial demonstrated that SP-104 was better tolerated than immediate release naltrexone hydrochloride 4.5 mg at the same dose in healthy volunteers.

Praxis Precision Medicines, Inc. announced that management will participate in the following upcoming investor conferences:

Abbott (NYSE: ABT) today announced a new partnership with Women as One to launch a new program designed to train more female and underrepresented physicians to pursue clinical trial research and help recruit clinical trial participants from historically underrepresented groups.